公开(公告)号：US20210228607A1

公开(公告)日：2021-07-29

申请号：US17051117

申请日：2019-04-24

Applicant: LEMONEX INC. ,  SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Cheol Hee WON ,  Dal Hee MIN

IPC: A61K31/7036 ,  A61K38/14 ,  A61K31/4706 ,  A61K31/5415 ,  A61K31/536 ,  A61K31/661 ,  A61K31/47 ,  A61K31/496 ,  A61K31/282 ,  A61K31/546 ,  A61K31/7048 ,  A61K38/12 ,  A61P31/14

Abstract: A method for treating a flavivirus infection includes administering to a subject in need thereof a composition which includes at least one of gentamicin sulfate, netilmicin, tobramycin, paromomycin, amikacin, capreomycin, trifluoperazine, dihydrostreptomycin, hydroxychloroquine, thioridazine HCl, efavirenz, miltefosine, nystatin, micafungin, bleomycin, resminostat, montelukast, norfloxacin, nedaplatin and cephalothin, which can exhibit excellent growth inhibition or killing effects of various species of flavivirus genus.

公开(公告)号：US20240139209A1

公开(公告)日：2024-05-02

申请号：US18277653

申请日：2022-02-17

Applicant: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION

Inventor： Dal Hee MIN ,  Ho Jeong SHIN

IPC: A61K31/573 ,  A61P31/14

CPC classification number: A61K31/573 ,  A61P31/14

Abstract: A pharmaceutical composition including a compound of Formula 1 may be used for preventing or treating dengue fever. Specifically, the composition may include ulipristal, ulipristal acetate, or a pharmaceutically acceptable salt thereof, which may inhibit dengue virus infection. The dengue fever may be caused by infection with dengue virus DENV-1, DENV-2, DENV-3 or DENV-4.